Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...

Empaveli (systemic pegcetacoplan) for paroxysmal nocturnal hemoglobinuria and Syfovre (intravitreal pegcetacoplan) for geographic atrophy secondary to age-related macular degeneration. William ...

Plus, there's a chance the active ingredient in Syfovre, called pegcetacoplan, could earn approval as a treatment for patients with another pair of rare diseases: C3 glomerulopathy (C3G ...

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per ...

SYFOVRE, or any of its future products will warrant regulatory submissions to the FDA or equivalent foreign regulatory agencies; whether systemic pegcetacoplan will receive approval from the FDA ...

SYFOVRE commercial vials grew by approximately ... in early 2025 seeking approval of pegcetacoplan in C3G and IC-MPGN. The FDA did not require Apellis to wait to file with the full 52-week data.

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 ...

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product sales Grew SYFOVRE® (pegcetacoplan injection) demand by 7% quarter-over-quarter, with U.S. net product ...